Breast Cancer

Targeted tumor delivery of irinotecan through sacituzumab govitecan can help to reduce treatment-related toxicities, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.

Results from a study on Canadian women who did and did not participate in a population-based breast cancer screening program show that interval breast cancers are more aggressive and deadlier than screening-detected cancers.

There is a clear need for better therapies to treat triple-negative breast cancer, especially when progression-free survival is around 2%, says Aditya Bardia, MBBS, MPH, breast medical oncologist at Massachusetts General Hospital, Harvard Medical School.

A novel combination shows promise against advanced solid tumors, including triple-negative breast cancer, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science at MD Anderson Cancer Center.

Aspirin is a known anti-inflammatory agent, but few studies have investigated its use among African American women to reduce the risk of breast cancer.

A study out of Scotland has linked levels of 2 short-chain fatty acids in female patients with early-stage breast cancer to pathological complete response (pCR) to neoadjuvant chemotherapy.

Long-term study results show which mechanisms of early-onset puberty in adolescent girls may predispose them to a greater risk of developing breast cancer.

Study results show that among premenopausal women, adulthood second primary breast cancer may carry with it a 2-fold greater risk of death if they had undergone radiation treatment for cancer as a child or young adult.

With little research on the subject, the investigators sought out a connection between certain perinatal factors and risk of young-onset breast cancer in a sister-matched case-control study.

Questionnaire results from the first weeks of the coronavirus disease 2019 (COVID-19) pandemic show that breast cancer treatment delays happened more often for younger vs older women.

At diagnosis, approximately 6% of breast cancers are metastatic breast cancer (MBC), which although treatable is not curable. Experts predicted that 276,480 women and 2620 men would receive such a diagnosis in 2020.

Risks of all-cause mortality and breast cancer-specific mortality decreased when female patients followed a more anti-inflammatory diet after their diagnosis of postmenopausal invasive breast cancer.

The Adjuvant Platinum and Taxane in Triple-Negative Breast Cancer trial investigated this combination adjuvant treatment vs the standard-of-care anthracycline plus docetaxel among patients with operable disease.

The challenges of complying with payer mandates in biosimilars were discussed in a webinar sponsored by The American Journal of Managed Care® and The Center for Biosimilars®.